J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster Darzalex more than offset erosion from older products and a drop in sales for heart pumps it picked up in its 2022 acquisition of Abiomed.

The healthcare conglomerate reported second-quarter sales of $25.31 billion, up 6.6% from a year earlier and above analysts' average estimate of about $25.05 billion, according to LSEG data. Adjusted earnings were $2.90 per share, up 4.7% from a year ago and topping analyst expectations of $2.85.

It now expects sales of about $101.1 billion at the midpoint, from $100.8 billion previously. The company also raised its adjusted earnings per share forecast to $11.68 at the midpoint, from $11.55 previously.

The company said its pharmaceutical unit generated $16.38 billion in quarterly sales, ahead of analyst estimates of $16.1 billion.

Sales of its psoriasis and inflammatory bowel disease drug Tremfya rose 72.5% to $2 billion, compared with LSEG estimates of $1.74 billion. Tremfya has become increasingly important as J&J works to replace sales lost from Stelara, whose revenue has fallen sharply after losing its patent protection.

Second-quarter sales of blood cancer treatment Darzalex were $4.2 billion in the quarter, roughly in line with analyst estimates.

Sales at J&J's medical technology unit were $8.93 billion, slightly trailing analyst estimates.

CFO Joseph Wolk said in an interview that Abiomed sales in the quarter were hurt after publication of a U.K. study that raised questions about the use of Impella pumps during certain high-risk coronary procedures. Abiomed sales in the quarter fell 2% year over year, compared with 14% growth in the first quarter.

He said J&J expects the franchise to return to growth, particularly as the company releases more data showing the utility of the pumps.

"We have a big data set coming out probably in the first half of next year that should allay any fears," Wolk said. "When you have 28 platforms that generate at least $1 billion in revenue on an annual basis, we're not dependent on one asset."

Sinergia Empresarial continuará el seguimiento de esta información sobre j&J quarterly earnings beat Wall Street estimates on strength of medicines unit y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.